- Home
- CYPH vs ACRV Comparison
CYPH vs ACRV Comparison
Compare CYPH & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYPH | ACRV |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 52.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | CYPH | ACRV |
|---|---|---|
| Price | $0.75 | $1.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 2.0M | 836.2K |
| Earning Date | 03-16-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $691.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $1.05 |
| 52 Week High | $3.70 | $3.56 |
Technical Indicators
Market Signals| Indicator | CYPH | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 54.77 | 44.20 |
| Support Level | $0.54 | $1.46 |
| Resistance Level | $0.79 | $1.86 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 76.24 | 20.00 |
Price Performance
Historical ComparisonAbout CYPH Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc is a company developing novel therapies for patients with cancer and implementing a digital asset treasury plan focused on Zcash.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.